Does Hydroxychloroquine Lower Hematocrit?
Yes, hydroxychloroquine can lower hematocrit, along with other hematologic parameters including red blood cells, hemoglobin, white blood cells, lymphocytes, and platelets.
Evidence from Research and Drug Labeling
The most direct evidence comes from a 2023 animal study that specifically measured hematologic effects of hydroxychloroquine at therapeutic doses equivalent to those used in humans for malaria, lupus, and COVID-19. This study demonstrated that HCQ significantly lowered erythrocytes, hemoglobin, and hematocrit values 1. The study used doses comparable to human therapeutic regimens, making these findings clinically relevant.
The FDA drug label for hydroxychloroquine explicitly warns about hematologic toxicity, including myelosuppression that can manifest as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 2. The label specifically recommends monitoring blood cell counts periodically in patients on prolonged hydroxychloroquine therapy and discontinuing the drug if myelosuppression develops that cannot be attributed to the underlying disease 2.
Mechanism and Clinical Context
The hematologic effects appear to be dose-dependent and related to duration of therapy. The FDA labeling notes that if myelosuppression develops, the drug should be discontinued if it cannot be attributed to the disease being treated 2. This is particularly important because many conditions treated with hydroxychloroquine (such as systemic lupus erythematosus) can themselves cause cytopenias.
Additionally, hydroxychloroquine can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency 2. This represents a separate mechanism of hematocrit reduction through red blood cell destruction rather than suppressed production.
Clinical Monitoring Recommendations
Monitor complete blood counts periodically in all patients on prolonged hydroxychloroquine therapy. The frequency should be increased in patients with:
- Pre-existing cytopenias
- G6PD deficiency (screen before initiating therapy)
- Concomitant use of other myelosuppressive medications
- Underlying autoimmune conditions that independently affect blood counts
If hematocrit or other blood cell parameters decline significantly and cannot be attributed to disease activity, discontinue hydroxychloroquine and investigate alternative causes 2.
Important Caveats
The hematologic effects must be distinguished from disease-related cytopenias, particularly in patients with systemic lupus erythematosus or rheumatoid arthritis, where anemia and other cytopenias are common disease manifestations. The challenge lies in determining whether declining hematocrit represents drug toxicity or worsening disease activity—this requires careful clinical correlation with other disease markers and potentially a trial of drug discontinuation.